Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07535242

Serum GFAP, NfL, VEGF and Clinical Progression in Progressive MS

This study aimed to investigate whether the biomarkers GFAP, NfL, and VEGF-recently considered important guides for better understanding the pathophysiology of MS-also serve as indicators of clinical progression in MS.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Multiple Sclerosis Autoimmune Diseases Autoimmune Diseases of the Nervous System Demyelinating Autoimmune Diseases, CNS Demyelinating Diseases Immune System Diseases Nervous System Diseases

Age range

18 year–60 year

Sex eligibility

All sexes

Study type

Observational

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Confirmed diagnosis of MS
  • Progressive type MS
  • Voluntary participation
  • Age between 18-60 years
  • Cooperative
  • EDSS score ≥ 5.5

Exclusion criteria

  • Presence of another neurological disorder
  • Change in medication within the last 3 months
  • Relapse within the last 3 months

Treatment and study plan

Primary outcomes

  1. Expanded Disability Status Scale (EDSS)

    Time frame: Baseline

    The Expanded Disability Status Scale (EDSS) is a method of quantifying disability in multiple sclerosis. Scores range from 0 to 10, in 0.5-point increments, where 0 indicates normal neurological status and 10 indicates death due to multiple sclerosis. The scale is based on the assessment of functional systems and ambulation, with higher scores reflecting greater disability.

  2. Standardized Mini-Mental Test

    Time frame: Baseline

    The Standardized Mini-Mental Test (MMT/MMSE) score ranges from 0 to 30. Higher scores indicate better cognitive function.

  3. Symbol Digit Modalities Test

    Time frame: Baseline

    The Symbol Digit Modalities Test (SDMT) is a neuropsychological test used to assess information processing speed, attention, and visual-motor coordination.

    Score range: Typically 0 to ~110 (number of correct responses in 90 seconds; exact upper limit depends on performance) Higher scores: Indicate better cognitive processing speed and function

  4. Multiple Sclerosis Impact Scale (MSIS-29)

    Time frame: Baseline

    Score range: 29-145 (each item scored 1-5) Higher scores: Indicate greater impact of MS on daily life (worse physical and psychological status)

  5. Glial Fibrillary Acidic Protein (GFAP)

    Time frame: Baseline

    This biomarker will be analyzed using the Enzyme-Linked Immunosorbent Assay (ELISA)

  6. Neurofilament Light Chain (NfL)

    Time frame: Baseline

    This biomarker will be analyzed using the Enzyme-Linked Immunosorbent Assay (ELISA).

  7. Vascular Endothelial Growth Factor (VEGF)

    Time frame: Baseline

    This biomarker will be analyzed using the Enzyme-Linked Immunosorbent Assay (ELISA).

Study contacts

Contact information is provided by the study sponsor or research team.

Seda Nur Kemer

CONTACT

[email protected]

+903623121919

Sponsors and collaborators

Lead sponsor

Ondokuz Mayıs University

Other

Registry information

Official study title

Investigation of the Relationship Between Serum GFAP, NfL, and VEGF Levels and Clinical Progression Markers in Progressive Multiple Sclerosis

Important dates

Study start
2026
Primary completion
2026
Study completion
2026
First posted
Apr 17, 2026
Registry last updated
Apr 17, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.